Authors

Milind Javle, MD, The University of Texas MD Anderson Cancer Center

Latest:

The Investigational Pipeline for Advanced BTC

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.

Hideaki Bando, MD, PhD

Hideaki Bando, MD, PhD is a medical oncologist in the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East, in Japan.

Latest:

Dr Bando on Safety of TAS-102 in MRD+ Resected CRC

Hideaki Bando, MD, PhD, discusses the safety of trifluridine/tipiracil in patients with MRD following resection of CRC.

Pierre Gholam, MD

Latest:

Dr Gholam on Camrelizumab Plus Rivoceranib in Unresectable HCC

Pierre Gholam, MD, discusses findings from the phase 3 CARES-310 trial of camrelizumab plus rivoceranib in patients with unresectable hepatocellular carcinoma.

Arpit Rao, MD

Latest:

Dr. Rao on the Rationale of the CASPAR Trial in mCRPC

Arpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.

Julio Gutierrez, MD

Latest:

Safety Profiles of Available Therapies in Advanced HCC

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Afsaneh Barzi, MD, PhD

Latest:

Dr Barzi on the Real-World Use of Triplet Chemotherapies in mCRC

Afsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.

Hans C. Lee, MD

Latest:

Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.

Amandeep Salhotra, MD

Latest:

Insights Into Real-World Evidence in Chronic GVHD

Panelists discuss how real-world evidence shows lower response rates and shorter time to next treatment compared to clinical trials due to more advanced patient populations and different monitoring practices, while highlighting the potential value of combination therapies using multiple FDA-approved agents simultaneously despite the lack of formal trial data supporting such approaches.

Neil J. Shah, MBBS

Latest:

Dr Shah on Real-World Treatment and Outcomes in Metastatic RCC After IO/TKI Combos

Neil J. Shah, MBBS, discusses treatment patterns and clinical outcomes in metastatic renal cell carcinoma after an immuno-oncology/TKI combination.

Félix Guerrero-Ramos, MD, PhD, FEBU

Guerrero-Ramos is the coordinator of the urologic oncology unit and the bladder cancer unit at Hospital Universitario 12 de Octubre, in Madrid, Spain.

Latest:

Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC

Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.

Lucy Gilbert, MD, MSc

Latest:

Dr. Gilbert on Evaluating Mirvetuximab Soravtansine in Platinum-Agnostic Ovarian Cancer

Lucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

Khalid Matin, MD, FACP

Latest:

Community-Based Programs Have the Power to Remove Clinical Trial Barriers

Homogeneous trials present a missed opportunity to discover treatments that might be highly successful in a particular subset of patients.

Anna T. Levy, DO

Latest:

Dr. Levy on the Safety Profile, Dosing of Cabozantinib in HCC

Anna T. Levy, DO, discuses the safety profile and appropriate dosing of cabozantinib in patients with hepatocellular carcinoma.

Oladapo Yeku, MD, PhD, FACP

Latest:

Dr. Yeku on the Evaluation of COM701 Plus Nivolumab in Platinum-Resistant Ovarian Cancer

Oladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.

Sponsored Q&A by Dr. Wang

Giuseppe Barbesino, MD

Latest:

Novel Treatment Advances in Differentiated Thyroid Cancer

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

Matthew Brunner, MD

Latest:

Dr Brunner on the Heterogeneity of Relapsed Multiple Myeloma

Matthew Brunner, MD, discusses the heterogeneity of relapsed multiple myeloma and the various symptoms that patients could experience.

Dr. Robert Dreicer

Latest:

Assessing the Prostate Cancer Treatment Paradigm: Understanding When to Intensify Treatment

Sponsored Content by Astellas Pharma US, Inc. and Pfizer Inc.; Dr. Dreicer has been compensated for the development of this article.

Matthew A. Lunning, DO, FACP

Latest:

CAR T-cells as Third-line and Beyond Therapy for FL

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Kate Gasparini, PharmD, BCOP, BCPPS

Kate Gasparini, PharmD, BCOP, BCPPS, is a pediatric oncology clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center

Latest:

Dr Gasparini on Challenges With Oral Therapies in Pediatric Patients or Patients With Dysphagia

Kate Gasparini, PharmD, BCOP, BCPPS, discusses issues with administering oral agents in pediatric patients with cancer or patients with dysphagia.